Your browser doesn't support javascript.
loading
Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature.
Furui, Yu; Komori, Kazutoshi; Kurata, Takashi; Sakashita, Kazuo.
Afiliação
  • Furui Y; Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, JPN.
  • Komori K; Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, JPN.
  • Kurata T; Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, JPN.
  • Sakashita K; Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, JPN.
Cureus ; 15(6): e40213, 2023 Jun.
Article em En | MEDLINE | ID: mdl-37435276
ABSTRACT
Ifosfamide, which is widely used as a chemotherapeutic agent in various kinds of malignancies, sometimes causes neurotoxicity known as ifosfamide-induced encephalopathy (IIE). Herein, we report the case of a three-year-old girl who developed IIE during chemotherapy for Ewing's sarcoma and was treated with methylene blue as a prophylactic agent for IIE, after which she continued with ifosfamide and completed treatment without IIE recurrence. This case suggests that methylene blue may be effective in preventing the recurrence of IIE in pediatric patients. Further studies, including clinical trials, are needed to confirm the efficacy and safety of methylene blue in pediatric patients.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article